These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 16382464)

  • 1. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation.
    Firpi RJ; Zhu H; Morelli G; Abdelmalek MF; Soldevila-Pico C; Machicao VI; Cabrera R; Reed AI; Liu C; Nelson DR
    Liver Transpl; 2006 Jan; 12(1):51-7. PubMed ID: 16382464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The challenge of progressive hepatitis C following liver transplantation.
    Davis GL
    Liver Transpl; 2006 Jan; 12(1):19-21. PubMed ID: 16382454
    [No Abstract]   [Full Text] [Related]  

  • 3. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved liver function and decreased hepatitis C viral load after tacrolimus was replaced by cyclosporine.
    Lorho R; Turlin B; de Lajarte-Thirouard AS; Camus C; Lakehal M; Compagnon P; Meunier B; Boudjema K; Messner M
    Transplant Proc; 2005; 37(6):2871-2. PubMed ID: 16182838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C.
    Fernández I; Ulloa E; Colina F; Abradelo M; Jiménez C; Gimeno A; Meneu JC; Lumbreras C; Solís-Herruzo JA; Moreno E
    Liver Transpl; 2009 Aug; 15(8):948-55. PubMed ID: 19642125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial.
    Martin P; Busuttil RW; Goldstein RM; Crippin JS; Klintmalm GB; Fitzsimmons WE; Uleman C
    Liver Transpl; 2004 Oct; 10(10):1258-62. PubMed ID: 15376310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus recurrence after liver transplantation: influence of immunosuppressive regimens on viral load and liver histology.
    Oton E; Barcena R; Castillo M; Barreales M; Blesa C; Moreno-Planas JM; Barrios C; Garrido A; Cuervas V
    Transplant Proc; 2006 Oct; 38(8):2499-501. PubMed ID: 17097980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of cyclosporine microemulsion and tacrolimus in 39 recipients of living donor liver transplantation.
    Tanaka K; Lake J; Villamil F; Levy G; Marotta P; Mies S; de Hemptinne B; Moench C
    Liver Transpl; 2005 Nov; 11(11):1395-402. PubMed ID: 16237691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C after liver transplantation.
    Sheiner PA
    Semin Liver Dis; 2000; 20(2):201-9. PubMed ID: 10946424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcineurin inhibition and disease recurrence in the hepatitis C virus-positive liver transplant recipient.
    Pollard S
    Liver Int; 2004 Oct; 24(5):402-6. PubMed ID: 15482334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation.
    Cescon M; Grazi GL; Cucchetti A; Vetrone G; Ravaioli M; Ercolani G; Morelli MC; Piscaglia F; Tamè M; Pinna AD
    Liver Transpl; 2009 Jul; 15(7):782-9. PubMed ID: 19562715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation.
    Hasenbein W; Albani J; Englert C; Spehr A; Grabhorn E; Kemper MJ; Burdelski M; Ganschow R
    Pediatr Transplant; 2006 Dec; 10(8):938-42. PubMed ID: 17096762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection.
    Yoshida EM; Lilly LB; Marotta PJ; Mason AL; Bilodeau M; Vaillancourt M
    Ann Hepatol; 2013; 12(2):282-93. PubMed ID: 23396740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral and cellular immune monitoring might be useful to identify liver transplant recipients at risk for development of infection.
    Carbone J; Micheloud D; Salcedo M; Rincon D; Bañares R; Clemente G; Jensen J; Sarmiento E; Rodriguez-Molina J; Fernandez-Cruz E
    Transpl Infect Dis; 2008 Dec; 10(6):396-402. PubMed ID: 18657086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C.
    Margarit C; Bilbao I; Castells L; Lopez I; Pou L; Allende E; Escartin A
    Transpl Int; 2005 Dec; 18(12):1336-45. PubMed ID: 16297052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients.
    Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J
    Liver Transpl; 2006 May; 12(5):762-7. PubMed ID: 16528713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
    Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of immunosuppressive therapy on hepatitis C infection after renal transplantation.
    Kahraman A; Witzke O; Scherag A; Pütter C; Miller M; Dechêne A; Ross SR; Gerken G; Hilgard P
    Clin Nephrol; 2011 Jan; 75(1):16-25. PubMed ID: 21176747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.